Uncategorized

Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting

by Business Wire • 2021/09/30 • 0 Comments

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics announces positive interim phase I/II data for investigational gene therapy GT005 at Retina Society Annual Scientific Meeting.

Full Story →

← All endpoints achieved in second phase 3 trial of NOV03 for dry eye disease

RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting →

Post navigation